Calculating pharma’s future: Balancing investment and innovation amid uncertainty

Pharma’s future depends on daily decisions made before outcomes are certain.

Which treatment approaches deserve further investment? When should a development program change direction? Which scientific and manufacturing capabilities are important enough to secure for the long term?

Across pharma, these questions shape where resources go and which opportunities advance, and each requires weighing today’s evidence against expectations of what a treatment or technology could deliver in the future.

Recent headlines bring these calculations into focus. New approvals suggest opportunities to reduce the burden of treatment, even as clinical setbacks and shifting priorities prompt companies to reconsider their programs. Elsewhere, substantial deals and government interventions reveal different judgments about where future value lies, and who should control the capabilities behind it.

Here are some of the stories shaping those decisions.

The ramarketing review cuts through the headlines to explore the developments shaping life sciences, with a different ramarketing expert each month providing context, commercial perspective and the stories that matter most.

If you’d like to receive updates straight to your inbox, sign up here.

Introducing November’s sector expert

Leo Bear-McGuinness, Scientific Content Writer

Drawing on years of experience in science journalism, Leo develops a range of written materials, from blogs to eBooks, to communicate clients’ capabilities and expertise in accessible formats.

Rethinking treatment

GSK’s Jemperli received accelerated FDA approval for adults with stage II/III locally advanced rectal cancer whose tumors are microsatellite instability-high or mismatch repair deficient. The immunotherapy could help eligible patients avoid chemotherapy, radiation and surgery, offering a different approach to treatment for this defined population.

Another approval points toward changing expectations in chronic disease: Hibsago offers certain adults with hepatitis B the possibility of maintaining viral control after treatment ends. Across two trials, 19% of recipients maintained viral control and undetectable hepatitis B surface antigen 24 weeks after stopping all hepatitis B treatment.

More on this story…

• GSK’s Jemperli announcement, October 19: https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-approved-in-us-as-first-and-only-immunotherapy-for-adults-with-msi-hdmmr-locally-advanced-rectal-cancer/
• FDA’s Hibsago announcement, October 20: https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment

Reassessing the path forward

The calculation changed for EyePoint after Duravyu missed its primary endpoint in the Phase III LUCIA trial in wet age-related macular degeneration. The company plans to reduce its workforce by about 53% and prioritize diabetic macular edema, showing how pivotal results can reshape resource allocation.

Access to capital prompted a different reassessment at Caribou Biosciences, which plans to discontinue its two allogeneic CAR-T cell therapy programs and explore strategic alternatives. Despite its continued belief in the programs’ potential, Caribou cited difficulty securing the financing needed to advance them. Along with EyePoint’s decision to redirect resources, this decision shows how portfolio priorities can shift in response to both clinical evidence and access to capital. For CROs and CDMOs, those shifts can affect project continuity and outsourcing needs, making early discussions about sponsors’ funding milestones and development alternatives valuable when planning work and capacity.

More on this story…

• EyePoint’s announcement, October 19: https://rss.globenewswire.com/news-release/2026/10/19/3383318/0/en/eyepoint-announces-strategic-prioritization.html
• Caribou’s announcement, October 6: https://cariboubio.gcs-web.com/news-releases/news-release-details/caribou-biosciences-evaluate-strategic-alternatives

Investing in what comes next

As some programs face funding constraints, others are attracting substantial backing: Merck KGaA has agreed to acquire Silence Therapeutics in a transaction valuing its equity at approximately $1.3 billion. The proposed acquisition would bring an RNA interference pipeline led by divesiran, following positive Phase II results in the rare blood disorder polycythemia vera.

Where Merck’s proposed acquisition would bring an existing pipeline under its ownership, Zealand Pharma’s collaboration with Generate Biomedicines provides access to AI-enabled protein engineering to develop new candidates for metabolic diseases. Generate will receive $30 million upfront, with further payments dependent on milestones, allowing Zealand to stage its financial commitment as the work progresses. The approaches involve different commitments: acquiring a pipeline gives greater control over its development, whereas collaboration allows partners to combine complementary capabilities and link further investment to progress.

For pharmaceutical service providers, these investments could create demand for specialist development and manufacturing support as new candidates progress. Decisions about building those capabilities will need to account for the strength of the emerging pipeline and the uncertainty over which programs will advance far enough to sustain demand.

More on this story…

• Silence Therapeutics’ acquisition announcement, October 19: https://silence-therapeutics.com/investors/press-releases/press-releases-details/2026/Silence-Therapeutics-Enters-into-Agreement-to-be-Acquired-by-Merck-KGaA-Darmstadt-Germany/default.aspx
• Zealand–Generate collaboration announcement, October 13: https://www.globenewswire.com/news-release/2026/10/13/3380177/0/en/zealand-pharma-and-generate-biomedicines-enter-collaboration-and-license-agreement-to-develop-protein-therapeutics-engineered-with-ai-for-metabolic-diseases.html

Securing strategic capabilities

Beyond individual pipelines, Antheia has received a conditional US government commitment for a loan of up to $80 million to support domestic manufacturing of critical pharmaceutical ingredients. Subject to financial, technical and other requirements, the financing connects its biosynthesis technology with efforts to strengthen US medicine supply chains.

China’s proposed changes to its technology export controls also put ownership of innovation under scrutiny. The proposals would restrict certain transfers of biotechnology capabilities, while treating licensing and outsourced services differently from platform ownership transfers. If adopted, that distinction could influence how international partners access technology, favoring some collaboration models over outright acquisitions and informing decisions about where to establish development and manufacturing capabilities. The implications would depend on the final rules and how they are implemented.

More on this story…

• Antheia’s financing announcement, October 18: https://antheia.bio/antheia-secures-80-million-conditional-funding-commitment-from-department-of-wars-office-of-strategic-capital/
• China’s Ministry of Commerce consultation notice, October 16, in Chinese: https://www.mofcom.gov.cn/zwgk/zcfb/art/2026/art_0a31a3c9ac404f7a9b0e917ce3412997.html
• Ministry explanation of the proposals, in Chinese: https://www.mofcom.gov.cn/syxwfb/art/2026/art_a4acff07e134447fbe7bbeb486df3ea6.html

Final thoughts

Calculating pharma’s future means sustaining long-term ambition while adapting to changes in clinical evidence, access to funding and the policies governing international collaboration.

For drug developers and their service partners, that requires a clear view of what justifies continued investment and what would prompt a change of direction. Commitments grounded in that understanding can support progress without locking companies into assumptions that no longer hold.